PF4 IgG™

Designed to detect Heparin-Associated PF4 Antibodies of the IgG Type

Both IgM and IgA heparin-associated antibodies are found in some patients that develop HIT. However, the majority of clinically relevant heparin-associated antibodies are IgG antibodies. Several publications have shown that these IgG antibodies are more closely associated with the development of Type II HIT in comparison to IgM and IgA antibodies. For immunoassays, detection of only IgG antibodies was shown to improve the specificity of the assay with respect to the diagnosis of HIT. The PF4 Enhanced® assay which detects IgG, IgA and IgM heparin associated antibodies can be used a primary screening assay. The PF4 IgG™ which has been designed to detect only IgG heparin-associated antibodies can be used to further discriminate samples found to contain IgG, A and M Heparin-associated antibodies.

Gen-Probe’s PF4 IgG™ Solid Phase ELISA is a patented technology (US Patent# 5,972,718) for the detection of PF4 heparin-associated antibodies. A formulation change to the Stopping Solution has been identified for LIFECODES’ ELISA-based assays. The new solution will eliminate hazards that are associated with the current reagent, as well as eliminate special chemical disposal needs. Read More >>

• Fast - assay can be completed in 2 hours
• Cost effective
• Consistent ELISA reliability
• Up to 45 samples in duplicate

For In Vitro Diagnostic Use.

Learn more about how to improve the clinical significance of a positive PF4-heparin ELISA result.